Heartbeam (BEAT) investor relations material

Company background and technology

• Founded to address the lack of at-home 12-lead ECGs, inspired by a personal loss due to heart attack misrecognition.

• Developed a cable-free, synthesized 12-lead ECG platform for real-time, at-home use, with two FDA clearances as of December 2024.

• Core IP centers on 3D heart signal collection, enabling both handheld and patch form factors for broad cardiac monitoring applications.

• Proprietary technology miniaturizes vectorcardiography, transforming 3D signals into physician-readable 12-lead ECGs.

Market strategy and commercial launch

• Initial target market is 1.5 million patients in concierge and preventive cardiology, with pricing set at $500-$1,000 per year per patient on a subscription basis.

• High willingness to pay and physician recommendation observed in market research among high-net-worth and concierge practice patients.

• Strategy leverages physician practices as sales channels, aiming for deep adoption within executive health and cardiology-focused segments.

• Break-even expected within the initial 150,000-patient segment, with plans to scale to broader markets and achieve cash flow positive at 30,000 patients.

Product pipeline and innovation

• Platform includes the FDA-cleared handheld device, an on-demand 12-lead patch for ambulatory monitoring, and AI-driven features.

• Patch device targets the $2 billion ambulatory cardiac monitoring market, offering both arrhythmia and ischemia detection, with strong physician interest for market adoption.

• AI partnerships, notably with Mount Sinai, aim to bring predictive and screening algorithms to home ECGs, expanding beyond symptom-driven use.

• Ongoing clinical studies in Europe and Asia support indication expansion for heart attack detection.